Breaking Finance News

Zacks Investment Research downgraded Athersys, Inc. (NASDAQ:ATHX) to Hold in a report released today.

Zacks Investment Research has downgraded Athersys, Inc. (NASDAQ:ATHX) to Hold in a report released on 10/11/2016.

Previously on 8/15/2016, Zacks Investment Research reported about Athersys, Inc. (NASDAQ:ATHX) raised the target price from $0.00 to $2.25. At the time, this indicated a possible upside of 0.12%.

Yesterday Athersys, Inc. (NASDAQ:ATHX) traded -5.36% lower at $2.12. The company’s 50-day moving average is $2.00 and its 200-day moving average is $2.17. The last stock close price is down -2.30% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 341,637 shares of the stock were exchanged, up from an average trading volume of 335,426

See Chart Below

Athersys, Inc. (NASDAQ:ATHX)

Athersys, Inc. has a 52 week low of $0.94 and a 52 week high of $2.90 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 4 firms have reported on the stock. The consensus target price is $4.25 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Athersys, Inc. (NASDAQ:ATHX)

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *